Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer

Background. Prostate cancer (PCa) is one of the most common malignancy in men. A traditional marker in the laboratory diagnosis ofPCa is the prostatic specific antigen (PSA). However, the low specificity of this marker leads to a large number of unnecessary biopsies. The emergence of various modifications of PSA and tumor-specific genetic markers such as PCA3 and TMPRSS2ERG, have improved the diagnosis of PCa.

Objective. Investigation of the diagnostic significance of molecular genetic markers, PCA3 and TMPRSS2:ERG, and their comparison with markers based on PSA isoforms: free/total PSA ratio (%fPSA) and prostate health index (PHI).

Materials and methods. The study included 58 men with suspected PCa. All patients were defined PCA3 score and the presence of TMPRSS2:ERG fusion transcript in the urine sediment. Also, PHI and %fPSA were determined in 48 and 51 men, respectively.

Results. The area under the ROC-curve regardless of the value of PSA was higher for PCA3 score (0.773, p <0.001), than for %fPSA and PHI: 0.625 (p = 0.131) and 0.735 (p = 0.006), respectively. At clinical sensitivity >95 % PCA3 score had the highest specificity, positive and negative predictive values in men, regardless of the level of PSA: 65.22, 80.95, and 93.75 %, respectively. In men with PSA level of 2—10 ng/ml the area under the ROC-curve for PCA3, %fPSA and PHI was 0.776 (p = 0.001), 0.629 (p = 0.144) and 0.729 (p = 0.009), respectively. At high sensitivity (>95 %) characteristics of the diagnostic test PCA3 in men with a PSA level of 2—10 ng/ml also also exceeded those for PHIand %>fPSA. The negative predictive valuefor PCA3score in this group ofmen was 100 %. The sensitivity ofdetection ofthe TMPRSS2:ERG fusion transcript in urine was 37.14 %, specificity 86.96 %, and the positive predictive value was 81.25 %.

Conclusion. The use ofthe PCA3 score in combination with the detection of TMPRSS2:ERG fusion will improve the assessment of PCa risk in men with PSA levels between 2 and 10ng/ml (the “grey zone”).

1. Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2018. DOI: 10.3322/caac.21492.

2. Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71(4):618—29. DOI: 10.1016/j.eururo.2016.08.003.

3. Leyten G.H., Hessels D., Jannink S.A. et al. Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65(3):534—42. DOI: 10.1016/j.eururo.2012.11.014.

4. Hendriks R.J., Van Oort I.M., Schalken J.A. Blood-based and urinary prostate cancer biomarkers: A review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis 2017;20(1):12—9. DOI: 10.1038/pcan.2016.59.

5. Scattoni V., Lazzeri M., Lughezzani G. et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013;190(2):496—501. DOI: 10.1016/j.juro.2013.02.3184.

6. Yang Z., Yu L., Wang Z. PCA3 and TMPRSS2:ERG gene fusions as diagnostic biomarkers for prostate cancer. Chinese J Cancer Res 2016;28(1):65—71. DOI: 10.3978/j.issn.1000-9604.2016.01.05.

7. Zhou F., Gao S., Han D. et al. TMPRSS2:ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene 2019;38(22):4397-411. DOI: 10.1038/s41388-019-0730-9.

8. Martignano F., Rossi L., Maugeri A. et al. Urinary RNA-based biomarkers for prostate cancer detection. Clin Chim Acta 2017;473:96-105. DOI: 10.1016/j.cca.2017.08.009.

9. Catalona W.J., Partin A.W., Sanda M.G. et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185(5):1650-5. DOI: 10.1016/j.juro.2010.12.032.

10. Koo K.M., Mainwaring P.N., Tomlins S.A., Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol 2019;16(5):302-17. DOI: 10.1038/s41585-019-0178-2.

11. Carroll P.H., Mohler J.L. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. J Natl Compr Cancer Netw J Natl Compr Canc Netw 2018;16:620-3. DOI: 10.6004/jnccn.2018.0036.

12. Cui Y., Cao W., Li Q. et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep 2016;6:25776. DOI: 10.1038/srep25776.

13. Toropovskiy A.N., Nikitin A.G., Gordiev M.G. et al. Results of validation of the Prosta-Test kit designed for mRNA PCA3 detection using twosteps RT-real time PCR in clinical diagnostics of prostate cancer. Vestnik meditsinskogo instituta “REAVIZ” = Journal of the REAVIZ Medical Institution 2018;1:126-36. (In Russ.).

14. Pavlov K.A., Shkoporov A.N., Khokhlova E.V. et al. Development of a diagnostic test system for early noninvasive detection of prostate cancer based on PCA3 mRNA levels in urine sediment using quantitative reverse tanscription polymerase chain reaction (qRT-PCR). Vestnik RAMN = Bulletin of RAMS 2013;(5):45— 51. (In Russ.).

15. Merola R., Tomao L., Antenucci A. et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: A National Cancer Institute experience. J Exp Clin Cancer Res 2015;34(1):15. DOI: 10.1186/s13046-015-0127-8.

16. Apolikhin O.I., Sivkov A.V., Efremov G.D. et al. The first Russian experience of using PCA3 and TMPRSS2:ERG for prostate cancer diagnosis. Experimenta’naya klinicheskaya urologiya = Experimental Clinical Urology 2015;(2):30—5. (In Russ.).

17. Park K., Dalton J.T., Narayanan R. et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol 2014;32(3):206-11. DOI: 10.1200/JCO.2013.49.8386.

18. Wang Z., Wang Y., Zhang J. et al. Significance of the TMPRSS2:ERG gene fusion in prostate cancer. Mol Med Rep 2017;16(4):5450-8. DOI: 10.3892/mmr.2017.7281.

19. Fujita K., Nonomura N. Urinary biomarkers of prostate cancer. Int J Urol 2018;25(9):770-9. DOI: 10.1111/iju.13734.

20. Sanda M.G., Feng Z., Howard D.H. et al. Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. JAMA Oncol 2017;3(8):1085-93. DOI: 10.1001/jamaoncol.2017.0177.

21. Van Hoof A., Bunn W., Klein A., Albala D. Role of molecular diagnostics in prostate cancer. Surg Proced Core Urol Trainees 2018:151-77. DOI: 10.1007/978-3-319-57442-4_17.

22. Perdona S., Bruzzese D., Ferro M. et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013;73(3):227-35. DOI: 10.1002/pros.22561.

23. De la Calle C., Patil D., Wei J.T. et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy Naive men. J Urol 2015;194(1):65-72. DOI: 10.1016/j.juro.2015.01.091.